Researcher in Cancer Immunotherapy
Uppsala University is a comprehensive research-intensive university with a
strong international standing. Our ultimate goal is to conduct education and
research of the highest quality and relevance to make a long-term difference
in society. Our most important assets are all the individuals whose curiosity
and dedication make Uppsala University one of Sweden's most exciting
workplaces. Uppsala University has over 45,000 students, more than 7,000
employees and a turnover of around SEK 7 billion.
The Department of Immunology, Genetics and Pathology at Uppsala University
(www. igp.uu.se) has a broad research profile with strong research groups
focused on cancer, autoimmune and genetic diseases. A fundamental idea at the
department is to stimulate translational research and thereby closer
interactions between medical research and health care. Research is presently
conducted in the following areas: medical and clinical genetics, clinical
immunology, pathology, neuro-oncology, vascular biology, radiation science and
molecular tools. Department activities are also integrated with the units for
Oncology, Clinical Genetics, Clinical Immunology, Clinical Pathology, and
Hospital Physics at Akademiska sjukhuset, Uppsala. The department has teaching
assignments in several education programmes, including Master Programmes, at
the Faculty of Medicine, and in a number of educations at the Disciplinary
Domain of Science and Technology. The department has a yearly turnover of
around SEK 400 million, out of which more than half is made up of external
funding. The staff amounts to approximately 340 employees, out of which 100
are PhD-students, and there are in total more than 600 affiliated people.
Read more about our benefits and what it is like to work at Uppsala University
Cancer immunotherapy against the PD1/L1 axis has achieved remarkable benefits
in patients. However, challenges remain as >80% of patients fail to respond to
the treatment. Our research group aims to dissect the resistance mechanisms by
elucidating interactions between the human immune system and cancer cells. We
focus on studying the negative regulatory mechanisms which cancer cells employ
to hamper efficient anti-tumor immunity. In this project, we will develop
CRISPR/Cas9-based precise genome editing capabilities to investigate the
immune evasion mechanisms in human myeloid cells. The project will identify
and investigate novel pathways or drug targets that could enable immune cell-
mediated elimination of cancer cells. We believe that this project will
provide significant knowledge to advance our understanding and bring benefits
to patients who are currently less likely to benefit from immunotherapy. We
offer significant training opportunities in translational cancer immunology
research through our scientific network in academia and pharmaceutical
industry and prioritize individual development of the group members. For more
information, please read at https: // www. scilifelab.se/ researchers/yumeng-
We are looking for a motivated researcher with a strong expertise and
documented experience in translational cancer immunology and immunotherapy.
The candidate should have completed her/his Swedish doctoral (or foreign
equivalent) training in cancer immunology, immunology, cancer biology or
other relevant areas within four (4) years at the application deadline. The
candidate is required to have experiences in handling and isolating primary
human immune cells and analyzing immune cell phenotype and functions using
advanced flow cytometry. In addition, the applicant must have proven
experience in using CRISPR/Cas9 system to modify functions in human cancer and
primary immune cells as well as using in vivo mouse models to study the
efficacy and functions of cancer immunotherapeutics. It is essential for the
candidate to demonstrate solid experience in cell and molecular biology
techniques, western blotting, ELISA, PCR, handling of blood products.
Experiences with scientific software such as Graphpad, Flowjo, EndNote are
also required. It is also expected that the candidate should be confident in
conducting scientific discussions and is willing to collaborate with others as
well as working independently.
It is considered a merit if the candidate has experiences in co-culture models
using human cancer cells and primary immune cells. Previous publications in
peer-reviewed scientific journals as a lead author or oral presentations at
international conferences are considered advantageous. Interest or knowledge
on myeloid cell biology is viewed positively too.
Uppsala University strives to be an inclusive workplace that promotes equal
opportunities and attracts qualified candidates who can contribute to the
University's excellence and diversity. We welcome applications from all
sections of the community and from people of all backgrounds.
About the employment
The employment is a temporary position, 12 months. Scope of employment 100
%. Starting date 2022-02-19 or as agreed. Placement: Uppsala.
For further information about the position, please contact: Yumeng Mao,
0732676821, firstname.lastname@example.org .
Please submit your application by 25 October 2021, UFV-PA 2021/3742.
Are you considering moving to Sweden to work at Uppsala University? Find out
more about what it´s like to work and live in Sweden.
Please do not send offers of recruitment or advertising services.
Submit your application through Uppsala University's recruitment system.
Placement: Department of Immunology, Genetics and Pathology
Type of employment: Full time , Temporary position longer than 6 months
Pay: Individual salary
Number of positions: 1
Working hours: 100%
County: Uppsala län
Union representative: Seko Universitetsklubben email@example.com
Number of reference: UFV-PA 2021/3742
Last application date: 2021-10-25